10x Genomics said it acquired Proteintech Genomics to expand proteomics capabilities and strengthen multiomics workflows. The companies did not disclose the acquisition price. The move is aimed at combining 10x’s scalable single-cell and spatial platforms with Proteintech’s protein detection tools. Proteintech Genomics, founded in 2022, develops optimized and highly multiplexed proteomic assays designed for integration into single-cell and spatial analysis workflows. The company’s Human Discovery Panel is described as the largest antibody-based single-cell protein panel, enabling simultaneous profiling of hundreds of targets alongside transcriptomic measurements. 10x framed the acquisition around closing the tools gap in proteomics relative to transcriptomics and accelerating harmonized RNA–protein studies. For researchers, the integration could reduce workflow complexity when generating matched proteomic and transcriptomic datasets. For the industrial genomics ecosystem, the deal highlights continued consolidation around “end-to-end” multiomics platforms—where customers increasingly expect interoperable assay pipelines rather than separate vendors for each measurement modality.